The results of the PURPOSE 2 trial released in September 2024, showed that 99.9% of the 2,180 cisgender men and gender-diverse participants in the United States, South Africa, Peru, Brazil, Argentina, ...

The collaboration supports efforts for HIV prevention through PrEP, emphasizing Hetero’s commitment to improving HIV care.

Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too ...

It is one of six global partners to have signed a voluntary licence agreement with Gilead to produce a high-quality generic ...

Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...

The Israeli military issued evacuation warnings for 20 more towns and villages in southern Lebanon, signaling a potential ...

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three ...

International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company ...

HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV prevention.

Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its ...

Surprise: Hannah and I switched Slog days. Because I respect tradition, we’ll begin with the weather, which is quite nice ...